Rion

We are hiring a Sr. Scientist, Quality Control. This is a unique opportunity to work at a leading clinical-stage regenerative medicine company at the forefront of exosome innovation. Apply now using the link below and become a pivotal part of RION's mission to innovate and transform patient care. https://lnkd.in/eBNwFtrb #JobOpening #BiotechCareers #RION #RochesterMNJobs #JoinOurTeam

Excited to share this case report of PEP curing a non-healing radiation wound. Tremendous testament of Dr. Van Able's dedication to her patients and the Rion team's work to provide PEP exosomes for this clinical effort.

🙌

We are excited to announce that the first patient has been dosed in the Phase 2 clinical trial of our Purified Exosome Product™ (PEP™) for Diabetic Foot Ulcers (DFU), marking a pivotal moment in our journey towards revolutionizing regenerative medicine.   Building upon the insights gained from our earlier studies, this Phase 2 trial will enroll 40 participants across multiple centers in a rigorous, prospective, open-label, and randomized study to evaluate the safety and efficacy of our novel topical treatment with PEP™. Over 12 weeks, we will compare the outcomes of subjects treated with PEP™ against those receiving the Standard of Care. “Dosing the first patient in the Phase 2 trial is a key milestone for RION and for the advancement of exosome science and the treatment of diabetic foot ulcers,” stated Dr. Atta Behfar, Co-founder of RION. “This trial is not just a test of a new therapeutic option; it is a step forward in our commitment to addressing the severe impacts of chronic wounds, which affect millions and pose significant economic burdens on healthcare systems globally.” For more details about this exciting development and our groundbreaking PEP™ technology, please read our full press release by clicking the link below. https://lnkd.in/eW7tqXfX

RION was honored to welcome U.S. Congressman Brad Finstad to our headquarters in Rochester, MN. During his visit, the Congressman toured the facilities, met our staff, and learned more about RION's breakthrough advancements in exosome technology and its potential to revolutionize healthcare. This important visit underscored RION's unwavering commitment to Minnesota’s economic landscape, demonstrated through our substantial investments in infrastructure, cutting-edge research and development, and the creation of numerous employment opportunities. As we continue on this path of innovation and discovery, we remain inspired by the potential of our work and the impact it promises for healthcare and our community. We extend our heartfelt thanks to Congressman Finstad for his visit and insightful engagement, and we eagerly look forward to furthering our shared goals of fostering economic growth and healthcare advancement.

RION recently hosted a blood drive in Rochester, MN, where our team, families, and community members donated blood. We recognize the importance of supporting our community through blood donations which indirectly supports our regenerative medicine applications that rely on platelets. Platelets are crucial for our regenerative medicine technology, as we biomanufacture regenerative exosomes vital for our tissue repair initiatives to help those in need “heal from within.” We've developed a proprietary process to isolate these exosomes from donated platelets, enabling mass production and scalability. Notably, RION utilizes platelets from blood donations nearing expiration, preventing waste and not drawing from the active blood supply.   Donating blood saves lives by providing essential transfusions for those in need, from accident victims to patients undergoing surgery or battling illness. Every two seconds, someone in the U.S. needs blood, emphasizing its essential role in community health. We extend our thanks to all blood donors for their support and encourage others who are considering donating blood to contact their local blood bank.    #RIONBloodDrive #RION #Exosomes #RegenerativeMedicine #Platelets

We are proud to announce the expansion of our manufacturing operations with a state-of-the-art facility in Rochester, Minnesota. This significant development enables RION to scale up the production of the acclaimed (plated)™ Skin Science brand by Rion Aesthetics, which harnesses the innovative power of platelet-derived exosomes for various aesthetic applications.   The expansion is a testament to RION's dedication to pioneering science and sophisticated manufacturing capabilities, especially in scaling up exosome production—a critical challenge within the industry. With this new facility, we are strategically positioned to meet the growing demand for the (plated)™ Skin Science brand, which is already making transformative strides in the aesthetic sector.   We would like to extend our gratitude to Minnesota Governor Tim Walz, the Minnesota Department of Employment and Economic Development (DEED), the Rochester Area Economic Development, Inc. (RAEDI), and the Rochester City Council for their pivotal support in this venture. Their confidence in our vision has been instrumental in achieving this milestone, and we eagerly anticipate furthering our impact on Minnesota's economy through groundbreaking research, job creation, and collaborative partnerships.   For additional insights into our enhanced exosome production capabilities and the implications of our latest expansion, we invite you to read our detailed press release. Please click the link below for more information.   https://lnkd.in/evBFeKhE    #RION #Exosomes #Innovation #EconomicGrowth #Minnesota

We are excited to be making headlines again! This time, we're announcing that Dr. Atta Behfar, Co-Founder & Executive Board Member, will be presenting at the Evercore ISI 2024 Emerging Biotech Conference.   Don't miss Dr. Behfar's fireside chat:   Date: Tuesday, February 28, 2024 Time: 04:35 PM EST   Dr. Behfar will spotlight RION's transformative journey in regenerative medicine, focusing on our innovative platelet-derived exosome technology. Presenting at the Evercore ISI Emerging Biotech Conference is not only an honor but also a remarkable opportunity to highlight Rion's pioneering research and development in regenerative exosome technology. Our presentation will delve into the transformative potential of our Purified Exosome Product™ (PEP™) and its far-reaching implications in regenerative medicine.   Join us to explore Rion's transformative journey in regenerative medicine and our innovative exosome technology. This event offers an excellent opportunity to network with industry leaders, share insights, and discover potential collaborations.

Did you know that Diabetic Foot Ulcers (DFUs) affect approximately 18.6 million people worldwide annually? This condition not only leads to amputations every 3 and a half minutes but also results in increased mortality, excruciating pain, and mobility issues, costing the U.S. healthcare system alone $13 billion.   We are proud to have initiated our Phase 2A study to assess the efficacy and safety of our internationally recognized exosome regenerative therapeutic, known as the Purified Exosome Product™ (PEP™), in the management of DFUs. Our Phase 2A study of PEP™ underscores our dedication to advancing exosome-based therapies, aiming to transform the management and outcomes of this challenging condition. With no new biologics approved for DFU by the FDA since the late 1990s, RION's pioneering efforts in exosome-based therapies are more vital than ever.   For more information about our trial and to gain deeper insight into our breakthrough regenerative exosome technology, please read our press release by clicking the link below. https://lnkd.in/ervYnYQU    #RION #RegenerativeMedicine #Exosomes #DiabeticFootUlcer #Diabetes

We are hiring a Quality Control Analyst. This is a unique opportunity to work at a leading clinical-stage regenerative medicine company at the forefront of exosome innovation. Apply now using the link below and become a pivotal part of RION's mission to innovate and transform patient care. https://lnkd.in/g6NwfwaA #JobOpening #BiotechCareers #RION #RochesterMNJobs #JoinOurTeam